Impact of Catheter Ablation on Quality of Life and Healthcare Utilisation-Reference-Cited by-同舟云学术

Impact of Catheter Ablation on Quality of Life and Healthcare Utilisation

Published:2021-12-15 Issue:4 Volume:10 Page:258-261
ISSN:2050-3369
Container-title:Arrhythmia & Electrophysiology Review
language:en
Short-container-title:Arrhythm Electrophysiol Rev

Author:

Mohanty Sanghamitra¹,Natale Andrea¹²³

Affiliation:

1. Texas Cardiac Arrhythmia Institute, St David’s Medical Center, Austin, TX, US

2. Interventional Electrophysiology, Scripps Clinic, San Diego, CA, US

3. Metro Health Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, US

Abstract

Impairment of quality of life (QoL) is a well-known complication of AF. Because of the association of AF with older age and many other cardiovascular comorbidities, there are multiple factors that could influence QoL score even after successful AF intervention. However, substantial improvement in QoL has been reported following catheter ablation for AF regardless of ablation outcomes. In terms of healthcare resource utilisation, the expenses associated with AF are very high because of the hospitalisations for AF-related thromboembolic complications, aggravation of heart failure, AF interventions, and emergency room visits for incessant arrhythmia episodes, and they represent a large economic burden worldwide. Several trials have shown a drastic reduction in healthcare costs following successful AF ablation. In this review, the authors discuss this evidence systematically.

Publisher

Radcliffe Group Ltd

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference36 articles.

1. Mohanty S, Mohanty P, Di Biase L, et al. Influence of body mass index on quality of life in atrial fibrillation patients undergoing catheter ablation. Heart Rhythm 2011;8:1847-52. https://doi.org/10.1016/j.hrthm.2011.07.005; PMID: 21740879.

2. Andrade JG, Macle L, Verma A, et al; CIRCA-DOSE Study Investigators. Quality of life and health care utilization in the CIRCA-DOSE Study. JACC Clin Electrophysiol 2020;6:935-44. https://doi.org/10.1016/j.jacep.2020.04.017; PMID: 32819528.

3. Nielsen JC, Johannessen A, Raatikainen P, et al. Long-term efficacy of catheter ablation as first-line therapy for paroxysmal atrial fibrillation: 5-year outcome in a randomised clinical trial. Heart 2017;103:368-76. https://doi.org/10.1136/heartjnl-2016-309781; PMID: 27566295.

4. Imberti JF, Ding WY, Kotalczyk A, et al. Catheter ablation as first-line treatment for paroxysmal atrial fibrillation: a systematic review and meta-analysis. Heart 2021;107:1630-6. https://doi.org/10.1136/heartjnl-2021-319496; PMID: 34261737.

5. Santangeli P, Di Biase L, Natale A. Ablation versus drugs: what is the best first-line therapy for paroxysmal atrial fibrillation? Antiarrhythmic drugs are outmoded and catheter ablation should be the first-line option for all patients with paroxysmal atrial fibrillation: pro. Circ Arrhythm Electrophysiol 2014;7:739-46. https://doi.org/10.1161/CIRCEP.113.000629; PMID: 25140019.